Early Detection of Prostate Cancer by FACS

Ziv Hospital1 site in 1 country40 target enrollmentAugust 2007

ConditionsProstate Cancer Hyperplasia

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Prostate Cancer
Sponsor: Ziv Hospital
Enrollment: 40
Locations: 1
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Early detection of prostrate cancer and development of metastases. The research will attempt to match the SCM test (structuredness of the cytoplasmic matrix) in lymphocytes as an early cancer detection test using Florescent Activated Cell Sorting (FACS) as a replacement for the CellScan instrument. The test is based on measurement of cellular changes in response to the specific prostate antigen, PSA.

Registry

clinicaltrials.gov

Start Date

August 2007

End Date

TBD

Last Updated

18 years ago

Study Type

Observational

Sex

Male

Investigators

Sponsor

Ziv Hospital

Eligibility Criteria

Inclusion Criteria

•Experimental group : Males between the ages of 60-90 years, with medical diagnosis of prostate cancer according to both clinical and hematological examinations, before receiving any medical treatment.
•Control Group 1: Males between the ages of 60-90 years, with diagnosed benign prostate hyperplasia -BPH.
•Control Group 2: Males between the ages of 60-90 years, medically diagnosed as healthy.
•Control Group 3: Males between the ages of 60-90 years, medically diagnosed with another form of cancer, not prostate.

Exclusion Criteria

•Experimental group: Other known cancer or systemic infection. Control Group 1: Other known cancer or systemic infection. Control Group 2:Past hematological disorders nor cancer growth history. other known systemic infection, nor urinary tract infection. Patients hospitalized for orthopedic injuries of any type who are otherwise free of urinary tract infections.
•Control Group 3:Other known systemic infection, nor urinary tract infection.